Coronavirus Notebook: Pfizer/BioNTech On Plans For EU Vaccine Rollout, COVAX Strikes New Deals
The latest round-up from the Pink Sheet of developments relating to COVID-19.
You may also be interested in...
Pfizer and BioNTech’s Comirnaty supply under existing agreements will continue as planned despite anticipated expansion into a new child sub-population in Europe.
The speed of the new messenger RNA platforms could once again come to the rescue, but fortunately the existing vaccines should remain effective against the emerging strain.
The first COVID-19 vaccine will shortly be available to the EU member states, after the European Commission today approved Pfizer/BioNTech's BNT162b2 just hours after the European Medicines Agency issued a positive opinion on the product. The EMA says that uncertainties remain over the ability of the vaccine to prevent transmission of the coronavirus and whether the new variant strain will render this and other vaccines less effective.